Table.
Characteristics of clinical trials
| Author | Year | Country | Design | Interventional therapies | Number of patients | Male (number) | Age (mean) | Child-Pugh class (A/B/C) (n) | MELD score (mean) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Luo et al. (20) | 2019 | China | Retrospective study | TACE+TIPS/ TACE | 212/136 | 191 | 46.32/44.79 | 54/129/34; 33/83/20 | 10.21/ 11.37 |
| 2 | Miura et al. (19) | 2015 | USA | Retrospective study | TACE+TIPS | 16 | 12 | 60.5 | 2/12/2 | 12.5 |
| 3 | Wang et al. (18) | 2014 | China | Retrospective study | TACE+TIPS | 19 | 17 | 54 | NA | 13.37 |
| 4 | Kuo et al. (11) | 2013 | USA | Retrospective study | TACE+TIPS/ TACE | 10/23 | 28 | 59/58 | NA | 14/12 |
| 5 | Ruohoniemi et al. (21) | 2020 | USA | Retrospective study | TACE+TIPS/ TACE | 25/25 | 37 | 60/61 | NA | 13/9 |
| 6 | Kang et al. (17) | 2012 | Korea | Retrospective study | TACE+TIPS | 20 | 15 | 56.6 | 7/11/2 | NA |
TACE, transcatheter arterial chemoembolization; TIPS, transjugular intrahepatic portosystemic shunt; MELD, model for end-stage liver disease; NA, not available.